About Gendicine

Gendicine was used in clinical trials on patients with late-stage HNSCC. After 8 weeks of therapy involving 1 injection per week, 64% of patients' tumors experienced complete regression and 32% experienced partial regression. In combination with chemo- and radiotherapy, Gendicine improved treatment efficacy more than 3-fold.

PDF format.